Xenetic Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Xenetic Biosciences Inc XBIO.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -83 cents. The lone analyst forecast for the quarter was for a loss of 64 cents per share.

• Revenue fell 18.8% to $589.90 thousand from a year ago; analysts expected $640.00 thousand.

• Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 45 cents​.

• The company reported a quarterly loss of $688.7 thousand.

• Xenetic Biosciences Inc shares had fallen by 29.6% this quarter and lost 30.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 19% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

This summary was machine generated from LSEG data August 12 at 09:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)